Early detection is crucial in the battle against breast cancer. This systematic review explores the potential of artificial intelligence (AI) in predicting future breast cancer risk using mammograms. We analyze existing studies to evaluate the accuracy, reliability, and clinical implications of AI-driven risk assessment models. By understanding the strengths and limitations of these models, we aim to inform future research and clinical practice.
Breast cancer remains a significant public health concern worldwide. Early detection through regular mammograms has been instrumental in reducing mortality rates. However, mammograms have limitations in predicting future cancer risk. Recent advancements in artificial intelligence (AI) offer promising opportunities to improve breast cancer risk assessment. This review delves into the current state of AI-driven mammography-based breast cancer risk prediction models.
Artificial intelligence has made remarkable strides in various fields, including healthcare. In radiology, AI algorithms have demonstrated exceptional performance in detecting abnormalities in medical images. Specifically, AI-powered mammogram analysis has shown promise in identifying subtle signs of breast cancer that might be missed by human radiologists.
Beyond detecting existing cancers, AI has the potential to predict the likelihood of developing breast cancer in the future. By analyzing mammographic images, AI algorithms can identify subtle patterns and features associated with increased risk. These models could be used to prioritize screening, target preventive interventions, and ultimately reduce breast cancer mortality.
To conduct this review, we systematically searched relevant databases for studies investigating AI-driven mammography-based breast cancer risk prediction. Inclusion and exclusion criteria were defined to ensure the quality and relevance of included studies. The extracted data included study design, sample size, AI algorithm, performance metrics, and clinical implications.
The included studies demonstrated varying levels of accuracy in predicting breast cancer risk using AI-driven mammogram analysis. Several factors influenced model performance, including the type of AI algorithm, dataset size, and image quality. While some studies reported promising results, further research is needed to validate these findings in larger and more diverse populations.
The integration of AI-driven breast cancer risk prediction models into clinical practice could revolutionize preventive care. By identifying women at higher risk, healthcare providers can offer tailored screening and prevention strategies. However, challenges such as model interpretability, ethical considerations, and patient acceptance must be addressed.
AI-driven mammography-based breast cancer risk prediction holds significant promise for improving early detection and prevention. While the field is still in its early stages, the potential benefits are substantial. Continued research and development are essential to refine these models and translate them into clinical practice. By harnessing the power of AI, we can move closer to a future where breast cancer is a preventable disease.
1.
Le cancer et le COVID ont conduit le patient à une double transplantation de poumon.
2.
Effective for localizing small, non-palpable breast lesions is ultrasound-guided localization with magnetic seeds.
3.
Long-term study links chronic conditions in midlife to higher cancer risk and mortality
4.
Subcutaneous Cancer Immunotherapies Provide New Options for Physicians and Patients
5.
When does a melanoma metastasize? Implications for management
1.
Unlocking the Mysteries of Reticulocyte Counts: A Guide to Understanding Your Blood Results
2.
The Checkpoint Architect: Unraveling the Mechanisms of PD-L1 Regulation for the Next Generation of Small-Molecule Therapies
3.
Screening Efficacy, Molecular Precision, and Therapeutic Revolutions in Lung Cancer 2025
4.
Genetic Testing in Cancer Prevention: BRCA Mutations and Lynch Syndrome Unlocked
5.
Transforming Cancer Care: CAR T-Cell Therapy for Relapsed/Refractory NHL and ALL
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part II
2.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update)
3.
An In-Depth Look At The Signs And Symptoms Of Lymphoma
4.
Post Progression Approaches After First-line Third-Generaion ALK Inhibitors
5.
Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma - Part IV
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation